Back to News
Market Impact: 0.12
Pilatus Biosciences to Present Trials-in-Progress Poster on Phase 1 PLT012 for Solid Tumor Cancers at ESMO 2026
Source: Business Wire
Healthcare & Biotech
Pilatus Biosciences announced it will present a trials-in-progress poster for its Phase 1 PLT012 program in solid-tumor cancers at ESMO 2026. The announcement signals ongoing early-stage clinical development but provides no efficacy, safety, financial, or regulatory data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
- U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast